TriApex at ACT 2026
Nov 15–18, 2026 San Antonio, TX ~1.4k attendees Website
TriApex takes part in 4 sessions at ACT 2026 in San Antonio. Its program centres on nonclinical safety for new drug types, from a tiered evaluation framework for antibody-drug conjugates to complement activation risk from chemically modified antisense oligonucleotides. It also covers gene therapy injected into the inner ear and the toxicity of lipid-delivered siRNA drugs in monkeys.
| Organization | ACT 2026 Attendance |
|---|---|
TriApex Nanjing, China | ◆Platinum Supporter |
Chinese nonclinical and clinical CRO with NMPA GLP certification, presenting work on ADCs, oligonucleotides, siRNA and gene therapy. | Talk Mon Nov 16 7:00am–7:55am Poster Mon Nov 16 5:00pm–6:30pm Poster Mon Nov 16 5:00pm–6:30pm |
Instantly find 20 buyers from TriApex
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American College of Toxicology (ACT). Organization details are derived from ACT’s published program, exhibitor floor plan and supporter list, and each organization’s own website. Submit a correction